Skip to main content
. Author manuscript; available in PMC: 2015 May 30.
Published in final edited form as: Vaccine. 2014 Apr 13;32(26):3223–3231. doi: 10.1016/j.vaccine.2014.04.008

Figure 2. ARI-4175 as monotherapy decreased tumor volume and improved survival in M3-9-M and MC38-CEA tumor models.

Figure 2

A. CEA-tg C57BL/6 mice were implanted on day 0 with 1×106 M3-9-M cells intramuscularly on the flank. B. CEA-tg C57BL/6 mice were implanted on day 0 with 3×105 MC38-CEA cells subcutaneously on the back. In both models, mice were given ARI-4175 (200 μg/mouse/day) or vehicle by gavage beginning on day 4 when tumors became visible. Mice were treated continuously from day 4 to day 25 (indicated by gray bars). Tumor volume was assessed 2–3 times/week. Statistical analysis of survival based on the Wilcoxon rank-sum test was performed on the indicated days.